Human Immunodeficiency Virus 1 Non-Nucleoside Analog Reverse Transcriptase Inhibitor
33 drugs across 16 manufacturers|25 Generic,8 Brand
The Human Immunodeficiency Virus 1 Non-Nucleoside Analog Reverse Transcriptase Inhibitor class contains 33 NDCs from 16 manufacturers (25 generic, 8 brand), at an average NADAC of $24.84 per unit. Every drug, manufacturer, and price in this FDA-defined pharmacologic class is listed below.
Total Drugs
33
25G / 8B
Manufacturers
16
Avg $24.8358/unit
Avg 7d Change
-1.26%
Across 23 drugs with changes
7d Activity
of 33 total drugs
Class Price Trend
Monthly average NADAC price per unit, split by generic and brand
Manufacturer Breakdown
16 manufacturers producing drugs in this therapeutic class(2 pricing outliers)
and 4 more manufacturers
Follow this class across the site
These links connect the therapeutic class page to the specific suppliers, markets, and trend surfaces that help users keep exploring.
Top supplier
Mylan Pharmaceuticals Inc. manufacturer profile
Review the supplier with the strongest product footprint inside this therapeutic class.
Lead market
etravirine market page
Move from the therapeutic class into the molecule that appears most often in this class-specific portfolio.
Trend hub
Latest trend hub
Compare this class against the rest of the weekly NADAC trend surface.
Guide
Understanding NADAC pricing
Use the explainer when you need a plain-English refresher on how these class-level numbers are published and interpreted.
Frequently Asked Questions
How many drugs are in the Human Immunodeficiency Virus 1 Non-Nucleoside Analog Reverse Transcriptase Inhibitor class?
The Human Immunodeficiency Virus 1 Non-Nucleoside Analog Reverse Transcriptase Inhibitor class contains 33 NDCs from 16 manufacturers — 25 generic and 8 brand products.
What is the average price of Human Immunodeficiency Virus 1 Non-Nucleoside Analog Reverse Transcriptase Inhibitor drugs?
The average NADAC for the Human Immunodeficiency Virus 1 Non-Nucleoside Analog Reverse Transcriptase Inhibitor class is $24.8358 per unit across 33 NDCs.
Is generic cheaper than brand in the Human Immunodeficiency Virus 1 Non-Nucleoside Analog Reverse Transcriptase Inhibitor class?
Among products priced per EA, the average generic NADAC in this class is $7.9918, versus $77.4732 for brand — brand products average about 9.7× the generic price.
Which manufacturers make Human Immunodeficiency Virus 1 Non-Nucleoside Analog Reverse Transcriptase Inhibitor drugs?
16 manufacturers make drugs in the Human Immunodeficiency Virus 1 Non-Nucleoside Analog Reverse Transcriptase Inhibitor class. Ranked by number of NDCs, the largest are Mylan Pharmaceuticals Inc. (3), Janssen Products LP (3), Macleods Pharmaceuticals Limited (3), Camber Pharmaceuticals Inc. (3), Aurobindo Pharma Limited (3).
How has Human Immunodeficiency Virus 1 Non-Nucleoside Analog Reverse Transcriptase Inhibitor pricing changed recently?
Over the past 7 days, 8 NDCs in this class rose and 15 fell, with a class-wide average change of -1.3%.